Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IMMUNIC, INC. (IMUX)

Immunic to hold PMS R&D Day webinar on November 5, 2026, with presentation

Neutral Impact 2 of 5 product/contract Written later

Immunic, Inc. disclosed that it is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET. The company furnished a presentation for the event as Exhibit 99.1. The filing contains no financial results, guidance, or transaction terms.

Key points

  • PMS R&D Day webinar held via video conference on Thursday, November 5, 2026, 12:30 p.m. to 2:00 p.m. ET
  • Presentation dated November 5, 2026, furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
  • Forward-looking statements cite the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 trial in progressive multiple sclerosis

The filing

CompanyIMMUNIC, INC. (IMUX)
Form8-K, current report
Filed with the SECNov 5, 2026, 9:00 AM ET
Accession number0001193805-26-001432

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.